Results of Operations and Financial Condition. On August 6, 2026, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 27, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…

Director — Martin Madaus: Dr. Martin Madaus was elected as a new director of Haemonetics Corporation.

Results of Operations and Financial Condition. On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or o…

Director — Charles J. Dockendorff: Mr. Dockendorff will not stand for re-election at the Company’s 2026 Annual Meeting.

Regulation FD Disclosure. On March 2, 2026, Haemonetics Corporation (the “Company”) repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026 (the “Notes”). The Company paid an aggregate amount of $300,000,000 in cash, representing the outstanding principal amount of the Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the Notes prior to the close of b…

Results of Operations and Financial Condition. On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act…

Other Events. On January 9, 2026, Haemonetics Corporation (the “Company”) announced its acquisition of Vivasure Medical Limited (“Vivasure”), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Under the terms of the definitive agreement between the parties, the Company acquired all of the outstanding equity interests of Vivasure for €100 million, or approximately €52 million net of the value of certain previous investments and other loans ma…

Results of Operations and Financial Condition. On November 6, 2025, Haemonetics Corporation issued a press release announcing financial results for the second quarter ended September 27, 2025 and first half of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (t…

Results of Operations and Financial Condition. On August 7, 2025, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 28, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…

Costs Associated with Exit or Disposal Activities. In May 2025, the Board of Directors of the Company approved a new market and regional alignment initiative and delegated authority to the Company’s management to determine the details of the specific actions that will comprise the initiative. This new strategic initiative is designed to improve operational performance and reduce costs by directing the Company’s resources toward the markets and geographies that offer the greatest growth and po…

Results of Operations and Financial Condition. On May 8, 2025, Haemonetics Corporation (the “Company”) issued a press release announcing financial results for the fourth quarter and fiscal year ended March 29, 2025. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to…

COO — Frank W. Chan: The company hired an experienced executive from a competitor to fill a senior C-suite role (COO), which is a significant positive signal for operational leadership.

Results of Operations and Financial Condition. On February 6, 2025, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 28, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabi…

Executive Vice President — Josep Llorens: The executive is retiring with a planned transition period and assistance in finding a successor, indicating an orderly succession rather than a sudden loss.

Other Events. On December 3, 2024, Haemonetics Corporation (the “Company”) announced that it has entered into a definitive agreement to sell its whole blood assets within its Blood Center business unit to GVS, S.p.A (“GVS”), a leading manufacturer of filter solutions for applications in the healthcare and life sciences sectors. Under the terms of the agreement, GVS will acquire the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along w…

Results of Operations and Financial Condition. On November 7, 2024, Haemonetics Corporation issued a press release announcing financial results for the second quarter ended September 28, 2024 and first half of fiscal 2025. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subj…

Chief Technology Officer — Anila Lingamneni: The departure of the Chief Technology Officer, a senior executive, represents a significant loss of key management talent.

Results of Operations and Financial Condition. On August 8, 2024, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 29, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section…

Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement. The information set forth in

Unregistered Sales of Equity Securities. The information set forth under

Entry into a Material Definitive Agreement. Purchase Agreement On May 22, 2024, Haemonetics Corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with certain initial purchasers (the “ Initial Purchasers ”) agreeing, subject to customary conditions, to issue and sell $600 million principal amount of the Company’s 2.50% Convertible Senior Notes due 2029 (the “ Notes ”) to the Initial Purchasers. In addition, pursuant to the Purchase Agreement, the Company…

Regulation FD Disclosure. On May 22, 2024, Haemonetics Corporation issued a press release announcing that it had priced an offering of $600 million aggregate principal amount of convertible senior notes due 2029 in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended, and that it has entered into agreements to repurchase for $185.5 million in cash approximately $200.0 million in aggregate principal amount of its 0.00% Convertible Senior Notes due 2026 in priva…

Regulation FD Disclosure. On May 21, 2024, Haemonetics Corporation issued a press release announcing its intention to offer $525 million aggregate principal amount of convertible senior notes due 2029 in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition. On May 9, 2024 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 30, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities…

Termination of a Material Definitive Agreement. The information set forth under